Cargando…

Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease

In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype of LRRK2 and GBA Parkinson’s disease (PD), and on the prevalence of prodromal features among individuals at risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaler, Avner, Shenhar-Tsarfaty, Shani, Shaked, Yanay, Gurevich, Tanya, Omer, Nurit, Bar-Shira, Anat, Gana-Weisz, Mali, Goldstein, Orly, Kestenbaum, Meir, Cedarbaum, Jesse M., Orr-Urtreger, Avi, Giladi, Nir, Mirelman, Anat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283235/
https://www.ncbi.nlm.nih.gov/pubmed/32518334
http://dx.doi.org/10.1038/s41598-020-66319-9
_version_ 1783544260166942720
author Thaler, Avner
Shenhar-Tsarfaty, Shani
Shaked, Yanay
Gurevich, Tanya
Omer, Nurit
Bar-Shira, Anat
Gana-Weisz, Mali
Goldstein, Orly
Kestenbaum, Meir
Cedarbaum, Jesse M.
Orr-Urtreger, Avi
Giladi, Nir
Mirelman, Anat
author_facet Thaler, Avner
Shenhar-Tsarfaty, Shani
Shaked, Yanay
Gurevich, Tanya
Omer, Nurit
Bar-Shira, Anat
Gana-Weisz, Mali
Goldstein, Orly
Kestenbaum, Meir
Cedarbaum, Jesse M.
Orr-Urtreger, Avi
Giladi, Nir
Mirelman, Anat
author_sort Thaler, Avner
collection PubMed
description In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype of LRRK2 and GBA Parkinson’s disease (PD), and on the prevalence of prodromal features among individuals at risk, we collected, laboratory test results, blood pressure, demographic, cognitive, motor, olfactory and affective information enabling the assessment of each component of MS and the construction of the MDS prodromal probability score. The number of metabolic components and their levels were compared between participants who were separated based on disease state and genetic status. One hundred and four idiopathic PD, 40 LRRK2-PD, 70 GBA-PD, 196 healthy non-carriers, 55 LRRK2-NMC and 97 GBA-NMC participated in this study. PD groups and non manifesting carriers (NMC) did not differ in the number of metabolic components (p = 0.101, p = 0.685, respectively). LRRK2-PD had higher levels of triglycerides (p = 0.015) and higher rates of prediabetes (p = 0.004), while LRRK2-NMC had higher triglyceride levels (p = 0.014). NMC with probability rates for prodromal PD above 50% had higher frequencies of hypertriglyceridemia and prediabetes (p < 0.005, p = 0.023 respectively). While elevated triglycerides and prediabetes were more frequent among LRRK2 carriers, MS does not seem to influence GBA and LRRK2-PD phenotype.
format Online
Article
Text
id pubmed-7283235
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72832352020-06-15 Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease Thaler, Avner Shenhar-Tsarfaty, Shani Shaked, Yanay Gurevich, Tanya Omer, Nurit Bar-Shira, Anat Gana-Weisz, Mali Goldstein, Orly Kestenbaum, Meir Cedarbaum, Jesse M. Orr-Urtreger, Avi Giladi, Nir Mirelman, Anat Sci Rep Article In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype of LRRK2 and GBA Parkinson’s disease (PD), and on the prevalence of prodromal features among individuals at risk, we collected, laboratory test results, blood pressure, demographic, cognitive, motor, olfactory and affective information enabling the assessment of each component of MS and the construction of the MDS prodromal probability score. The number of metabolic components and their levels were compared between participants who were separated based on disease state and genetic status. One hundred and four idiopathic PD, 40 LRRK2-PD, 70 GBA-PD, 196 healthy non-carriers, 55 LRRK2-NMC and 97 GBA-NMC participated in this study. PD groups and non manifesting carriers (NMC) did not differ in the number of metabolic components (p = 0.101, p = 0.685, respectively). LRRK2-PD had higher levels of triglycerides (p = 0.015) and higher rates of prediabetes (p = 0.004), while LRRK2-NMC had higher triglyceride levels (p = 0.014). NMC with probability rates for prodromal PD above 50% had higher frequencies of hypertriglyceridemia and prediabetes (p < 0.005, p = 0.023 respectively). While elevated triglycerides and prediabetes were more frequent among LRRK2 carriers, MS does not seem to influence GBA and LRRK2-PD phenotype. Nature Publishing Group UK 2020-06-09 /pmc/articles/PMC7283235/ /pubmed/32518334 http://dx.doi.org/10.1038/s41598-020-66319-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Thaler, Avner
Shenhar-Tsarfaty, Shani
Shaked, Yanay
Gurevich, Tanya
Omer, Nurit
Bar-Shira, Anat
Gana-Weisz, Mali
Goldstein, Orly
Kestenbaum, Meir
Cedarbaum, Jesse M.
Orr-Urtreger, Avi
Giladi, Nir
Mirelman, Anat
Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
title Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
title_full Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
title_fullStr Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
title_full_unstemmed Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
title_short Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease
title_sort metabolic syndrome does not influence the phenotype of lrrk2 and gba related parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283235/
https://www.ncbi.nlm.nih.gov/pubmed/32518334
http://dx.doi.org/10.1038/s41598-020-66319-9
work_keys_str_mv AT thaleravner metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT shenhartsarfatyshani metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT shakedyanay metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT gurevichtanya metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT omernurit metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT barshiraanat metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT ganaweiszmali metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT goldsteinorly metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT kestenbaummeir metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT cedarbaumjessem metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT orrurtregeravi metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT giladinir metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease
AT mirelmananat metabolicsyndromedoesnotinfluencethephenotypeoflrrk2andgbarelatedparkinsonsdisease